DTP is Scaling Fast, but the Safety Infrastructure Is Not
DTP Is Scaling Fast, the Safety Infrastructure Is Not | Alvarez & Marsal
Summary
Alvarez & Marsal experts point out that while Direct-to-Patient (DTP) models are rapidly expanding, robust clinical infrastructure must be established to ensure patient safety. The lack of bidirectional medication visibility in Electronic Health Records (EHRs), in particular, increases drug-drug interaction risks and complicates care coordination.
Details
This article addresses the critical challenge facing pharmaceutical companies regarding Direct-to-Patient (DTP) investment. Examples like LillyDirect show that DTP is functioning as a demand-unlocking commercial channel rather than merely a compliance tactic. However, supporting this growth requires prioritizing clinical safety. Currently, EHRs have a 'blind spot' in bidirectional medication visibility, which increases the risk of drug-drug interactions and complicates adverse event management. While short-term mitigations include one-click PCP notifications and downloadable summaries, sustainable safety demands consented EHR messaging and full FHIR API integration to achieve interoperability. Sustainable advantage will stem from pairing convenience with clinical accountability, robust data governance, and interconnected records.
Original content copyright by respective publishers